Abstract
The relationship between estrogen and pituitary prolactinoma is well documented. The biological effects of estrogen are mainly mediated by estrogen receptor α (ERα). Several lines of evidence demonstrate that growth factors such as pituitary tumor transforming gene (PTTG), basic fibroblast growth factor (bFGF), transforming growth factor β1 (TGFβ1), transforming growth factor β3 (TGFβ3), and transforming growth factor β receptor type II (TGFβRII) play an important role in prolactinoma pathogenesis induced by estrogen, but the relationship between ERα and such growth factors is still unclear. The aims of this study are to investigate the functional role of ERα in proliferation, prolactin (PRL) secretion, and expression of the above-mentioned growth factors in MMQ cells in the absence of estrogen and to discuss the feasibility of using an estrogen receptor antagonist to treat prolactinoma. Fulvestrant, a “pure” antiestrogen without any estrogen-like activity, was used to block expression of ERα in the MMQ cell line. Proliferation and PRL secretion of MMQ cells were measured using CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) and the enzyme-linked immunosorbent assay (ELISA) method. Levels of ERα, PTTG, bFGF, TGFβ1, TGFβ3, and TGFβRII were analyzed by real-time polymerase chain reaction (PCR) and Western blot. Fulvestrant significantly inhibited cell proliferation (up to 60.80%) and PRL secretion (up to 77.95%), and changed expression of TGFβ3 and TGFβRII in the absence of estrogen. In conclusion, ERα plays an important functional role in proliferation and PRL secretion of pituitary prolactinomas and also can change expression of some growth factors even under the condition of no estrogen. Fulvestrant could potentially be an effective therapy for treating such tumors.
Similar content being viewed by others
References
Yin P, Arita J (2000) Differential regulation of prolactin release and lactotrope proliferation during pregnancy, lactation and the estrous cycle. Neuroendocrinology 72:72–79
Lloyd RV (1983) Estrogen-induced hyperplasia and neoplasia in the rat anterior pituitary gland. An immunohistochemical study. Am J Pathol 113:198–206
Molitch ME (1999) Management of prolactinomas during pregnancy. J Reprod Med 44(12 Suppl):1121–1126
Carol W, Lauterbach H, Klinger G, Unger A, Michels W (1988) Prolactin stimulation using the metoclopramide test in females taking oral contraceptives. Zentralbl Gynakol 110:1515–1521 (in German)
Shy KK, McTiernan AM, Daling JR, Weiss NS (1983) Oral contraceptive use and the occurrence of pituitary prolactinoma. JAMA 249:2204–2207
Elias KA, Weiner RI (1984) Direct arterial vascularization of estrogen-induced prolactin-secreting anterior pituitary tumors. Proc Natl Acad Sci U S A 81:4549–4553
Raymond V, Beaulieu M, Labrie F, Boissier J (1978) Potent antidopaminergic activity of estradiol at the pituitary level on prolactin release. Science 200:1173–1175
Sarkar Dk, Hentges ST, De A, Reddy RH (1998) Hormonal control of pituitary prolactin-secreting tumors. Front Biosci 3:d934–d943
Mosselman S, Polman J, Dijkema R (1996) ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 392:49–53
Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS (1994) Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem 269:4458–4466
Aronica SM, Katzenellenbogen BS (1991) Progestrone receptor regulation in uterine cells: stimulation by estrogen, cyclic adenosine 3′,5′-monophosphate, and insulin-like growth factor I and supression by antiestrogens and protein kinase inhibitors. Endocrinology 128:2045–2052
Beck CA, Weigel NL, Edwards DP (1992) Effects of hormone and cellular modulators of protein phosphorylation on transcriptional activity, DNA binding, and phosphorylation of human progesterone receptors. Mol Endocrinol 6:607–620
Sirbasku DA (1978) Estrogen induction of growth factors specific for hormone-responsive mammary, pituitary and kidney tumor cells. Proc Natl Acad Sci U S A 75:3786–3790
Soto AM, Sonnenschein C (1987) Cell proliferation of estrogen-sensitive cells: the case for negative control. Endocr Rev 8:44–52
Judd AM, Login IS, Kovacs K, Ross PC, Spangelo BL, Jarvis WD, MacLeod RM (1988) Characterization of the MMQ cell, a prolactin-secreting clonal cell line that is responsive to dopamine. Endocrinology 123:2341–2350
Wakeling AE, Dukes M, Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867–3873
Lykkesfeldt AE, Madsen MW, Briand P (1994) Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164, 384 and ICI 182, 780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res 54:1587–1595
Gottardis MM, Jiang SY, Jeng MH, Jordan VC (1989) Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49:4090–4093
Bross PF, Baird A, Chen G, Jee JM, Lostritto RT, Morse DE, Rosario LA, Williams GM, Yang P, Rahman A, Williams G, Pazdur R (2003) Fulvestrant in postmenopausal women with advanced breast cancer. Clin Cancer Res 9:4309–4317
Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG (1990) Inhibition of estrogen receptor-DNA binding by the “pure” antiestrogen ICI 164, 384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci U S A 87:6883–6887
Ignar-Trowbridge DM, Teng CT, Ross KA, Parker MG, Korach KS, McLachlan JA (1993) Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Mol Endocrinol 7:992–998
Improta-Brears T, Whorton AR, Codazzi F, York JD, Meyer T, McDonnell DP (1999) Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. Proc Natl Acad Sci U S A 96:4686–4691
Cenni B, Picard D (1999) Ligand-independent activation of steroid receptors: new roles for old players. Trends Endocrinol Metab 10:41–46
El-Tanani MK, Green CD (1997) Two separate mechanisms for ligand-independent activation of the estrogen receptor. Mol Endocrinol 11:928–937
Heaney AP, Singson R, McCabe CJ, Nelson V, Nakashima M, Melmed S (2000) Pituitary-tumour transforming gene in colorectal tumors. Lancet 355:712–715
Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S (1999) Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 5:1317–1321
Amano O, Yoshitake Y, Nishikawa K, Iseki S (1993) Immunocytochemical localization of basic fibroblast growth factor in the rat pituitary gland. Arch Histol Cytol 56:269–276
Elias KA, Weiner RI (1984) Direct arterial vascularization of estrogen-induced prolactin-secreting anterior pituitary tumors. Proc Natl Acad Sci U S A 81:4549–4553
Chaturvedi K, Sarkar DK (2004) Involvement of protein kinase C-dependent mitogen-activated protein kinase p44/42 signaling pathway for cross-talk between estradiol and transforming growth factor-beta3 in increasing basic fibroblast growth factor in folliculostellate cells. Endocrinology 145:706–715
Pastorcic M, De A, Boyadjieva N, Vale W, Sarkar DK (1995) Reduction in the expression and action of transforming growth factor β1 on lactotropes during estrogen-induced tumorigenesis in the anterior pituitary. Cancer Res 55:4892–4898
Minami S, Sarkar DK (1997) Transforming growth factor-β1 inhibits prolactin secretion and lactotropic cell proliferation in the pituitary of estrogen-treated Fischer 344 rats. Neurochem Int 30:499–506
Hentges S, Boyadjieva N, Sarkar DK (2000) Transforming growth factor-β3 stimulates lactotrope cell growth by increasing basic fibroblast growth factor from folliculo-stellate cells. Endocrinology 141:859–867
Brattain MG, Markowitz SD, Willson JKV (1996) The type II transforming growth factor-βreceptor as a tumor-suppressor gene. Curr Opin Oncol 8:49–53
Sarkar DK, Pastorcic M, De A, Engel M, Moses H, Ghasemzadeh B (1998) Role of transforming growth factor (TGF)-βtype I and TGF-β type II receptors in the TGF-β1-regulated gene expression in pituitary prolactin-secreting lactotropes. Endocrinology 139:3620–3628
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lv, H., Li, C., Gui, S. et al. Effects of estrogen receptor antagonist on biological behavior and expression of growth factors in the prolactinoma MMQ cell line. J Neurooncol 102, 237–245 (2011). https://doi.org/10.1007/s11060-010-0326-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-010-0326-2